SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies

NCT07738757 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies

Interventions

DRUG: Sacituzumab Tirumotecan (Sac-TMT)
DRUG: Tagitanlimab

Sponsor

Peking Union Medical College Hospital